本文選題：炎性乳腺癌 + 化療�。� 參考：《中國(guó)腫瘤臨床》2017年16期

【摘要】：目的:探討炎性乳腺癌(inflammatory breast cancer,IBC)患者臨床病理特征與新輔助化療療效及預(yù)后的相關(guān)關(guān)系。方法:回顧性分析天津醫(yī)科大學(xué)腫瘤醫(yī)院2010年1月至2013年12月收治且接受新輔助化療的81例IBC患者臨床資料,應(yīng)用單因素及多因素統(tǒng)計(jì)學(xué)方法分析其臨床病理特征對(duì)化療療效及預(yù)后的影響。結(jié)果:所有患者3年總生存(OS)率和無(wú)病生存(DFS)率分別為53.1%和37.0%,患者接受新輔助化療后的病理完全緩解(pathologic complete response,pCR)率為13.6%(11/81)。新輔助化療后是否達(dá)到pCR與患者的病理類型和分子分型有關(guān)(P0.05),但獲得pCR并不會(huì)改善其預(yù)后(P0.05),而IBC患者的術(shù)前淋巴結(jié)分期是OS和DFS的獨(dú)立影響因素(均P0.05),新輔助化療方案和淋巴管癌栓情況是影響患者DFS的獨(dú)立因素(P0.05)。結(jié)論:IBC的臨床病理特征影響患者對(duì)化療的敏感性,同時(shí)通過(guò)對(duì)術(shù)前淋巴結(jié)分期和淋巴管癌栓狀態(tài)的評(píng)估,可以預(yù)測(cè)疾病的預(yù)后,合理使用新輔助化療方案,以期達(dá)到最佳的治療效果。
[Abstract]:Objective: to investigate the relationship between the clinicopathological features of inflammatory breast cancer patients and the efficacy and prognosis of neoadjuvant chemotherapy. Methods: the clinical data of 81 patients with IBC who received neoadjuvant chemotherapy from January 2010 to December 2013 in Tianjin Medical University Oncology Hospital were retrospectively analyzed. Univariate and multivariate statistics were used to analyze the influence of clinicopathological features on the curative effect and prognosis of chemotherapy. Results: the total survival rate and disease-free survival rate of all patients were 53.1% and 37.0, respectively. The rate of pathologic complete responsepCRs after neoadjuvant chemotherapy was 13.6% and 11.81%, respectively. Whether or not to reach pCR after neoadjuvant chemotherapy is related to the pathological type and molecular type of patients. However, obtaining pCR does not improve the prognosis of IBC patients. The preoperative lymph node staging of IBC patients is an independent factor of OS and DFS (all P 0.05, neoadjuvant). The therapeutic regimen and lymphatic thrombus were independent factors affecting DFS in patients (P 0.05). Conclusion the clinicopathological features of WIBC influence the sensitivity of the patients to chemotherapy. By evaluating the preoperative lymph node staging and lymphatic thrombus status, the prognosis of the disease can be predicted and the neoadjuvant chemotherapy regimen can be used reasonably. In order to achieve the best therapeutic effect.
【作者單位】： 天津醫(yī)科大學(xué)腫瘤醫(yī)院乳腺二科國(guó)家腫瘤臨床醫(yī)學(xué)研究中心天津市腫瘤防治重點(diǎn)實(shí)驗(yàn)室乳腺癌防治教育部重點(diǎn)實(shí)驗(yàn)室;河北大學(xué)附屬醫(yī)院乳腺外科;
【分類號(hào)】：R737.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 宋向群;周建紅;于起濤;曾愛屏;周達(dá);何劍波;;晚期乳腺癌患者血清Her-2/neu濃度與化療療效的關(guān)系[J];中國(guó)癌癥防治雜志;2009年01期

2 王健;唐金海;鐘山亮;趙建華;孫鶴慶;張鳳霞;龔建平;季明華;;MDR1基因多態(tài)性與乳腺癌紫杉聯(lián)合蒽環(huán)類藥物化療療效的關(guān)系[J];中國(guó)腫瘤臨床;2011年01期

3 周鑫,孫治君;乳腺癌中基因表達(dá)對(duì)化療療效的預(yù)測(cè)[J];重慶醫(yī)學(xué);2005年03期

4 劉長(zhǎng)民;袁蘇徐;徐紅;李道明;馮軍;陳小玲;;貧血對(duì)乳腺癌輔助化療療效和預(yù)后的影響[J];實(shí)用癌癥雜志;2009年02期

相關(guān)會(huì)議論文 前1條

1 顧雅佳;馮曉源;邱龍華;彭衛(wèi)軍;楊文濤;費(fèi)菲;陳燦敏;;磁共振彌散成像對(duì)局部進(jìn)展期乳腺癌輔助化療療效評(píng)價(jià)的初步研究[A];中華醫(yī)學(xué)會(huì)第十三屆全國(guó)放射學(xué)大會(huì)論文匯編（下冊(cè)）[C];2006年

相關(guān)重要報(bào)紙文章 前1條

1 張中橋;中國(guó)~(18)F—FDG顯像評(píng)價(jià)化療療效[N];醫(yī)藥經(jīng)濟(jì)報(bào);2007年

，

本文編號(hào)：1802989